Orally bioavailable multi-kinase inhibitor with potent activity against c-MET (IC50 values 35 - 53 nM for cell-based activity), and several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1, DDR2 and against the serine/threonine kinases MKNK1 and MKNK2 (IC50 values 11, 7, 2, 10, 63, 23, 0.1, 7, 7, and 7 nM, respectively). In classic and orthotopic mouse xenograft models of lung cancer, LY2801653 decreased tumor growth, dramatically inhibiting mitotic events and angiogenesis.
KEYWORDS: LY 2801653 | supplier | Multi-kinase (c-MET) inhibitor | Merestinib | LY2801653 | CAS [1206799-15-6] | HGF | c-MET | MST1R | Axl | FLT3 | MERTK | TEK | ROS1 | DDR1 | DDR2 | RTKInhibitor | MKNK1 | MKNK2 | oncoproteins